Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Lenalidomide + rituximab (R²) is approved by both the FDA and EMA for specific indolent Non‑Hodgkin lymphoma subtypes.
The FDA approved this combination for adult patients with previously treated follicular lymphoma (FL) and marginal zone lymphoma (MZL) (1)
These approvals are based on the AUGMENT (NCT01938001) and MAGNIFY (NCT01996865) trials.
R² is established as a chemotherapy‑free…